154 related articles for article (PubMed ID: 35864053)
21. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.
Freedland SJ; Davis M; Epstein AJ; Arondekar B; Ivanova JI
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):327-333. PubMed ID: 37783836
[TBL] [Abstract][Full Text] [Related]
22. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
Buonerba C; Ferro M; Dolce P; Crocetto F; Verde A; Lucarelli G; Scafuri L; Facchini S; Vaia A; Marinelli A; Terracciano D; Montella L; Longo N; Imbimbo C; Mirone V; Di Lorenzo G; De Placido S; Sonpavde G
Crit Rev Oncol Hematol; 2020 Jul; 151():102992. PubMed ID: 32474391
[TBL] [Abstract][Full Text] [Related]
23. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
[TBL] [Abstract][Full Text] [Related]
24. Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Hamano I; Okamoto T; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Int J Urol; 2020 Jul; 27(7):610-617. PubMed ID: 32418347
[TBL] [Abstract][Full Text] [Related]
25. Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue.
Roviello G; Petrioli R; Villari D; D'Angelo A
Clin Genitourin Cancer; 2021 Feb; 19(1):83-86. PubMed ID: 32665085
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Naiki T; Takahara K; Ito T; Nakane K; Sugiyama Y; Koie T; Shiroki R; Miyake H; Yasui T
Int J Clin Oncol; 2022 Mar; 27(3):592-601. PubMed ID: 34779958
[TBL] [Abstract][Full Text] [Related]
27. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
28. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.
Shayegan B; Wallis CJD; Hamilton RJ; Morgan SC; Cagiannos I; Basappa NS; Ferrario C; Gotto GT; Fernandes R; Roy S; Noonan KL; Niazi T; Hotte SJ; Saad F; Hew H; Park-Wyllie L; Chan KFY; Malone S
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):74-79. PubMed ID: 35197558
[TBL] [Abstract][Full Text] [Related]
29. External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer.
Swami U; Sayegh N; Jo Y; Haaland B; McFarland TR; Nussenzveig RH; Goel D; Sirohi D; Hahn AW; Maughan BL; Goldkorn A; Agarwal N
Mol Cancer Ther; 2022 Dec; 21(12):1857-1861. PubMed ID: 36198026
[TBL] [Abstract][Full Text] [Related]
30. Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.
George DJ; Agarwal N; Ramaswamy K; Klaassen Z; Bitting RL; Russell D; Sandin R; Emir B; Yang H; Song W; Lin Y; Hong A; Gao W; Freedland SJ
Prostate Cancer Prostatic Dis; 2024 Apr; ():. PubMed ID: 38565911
[TBL] [Abstract][Full Text] [Related]
31. Far from the truth: Real-world treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification.
Yang X; Tan YG; Gatsinga R; Chen W; Huang HH; Loong JTK; Chua MLK; Rajasekaran T; Kanesvaran R; Tay KJ; Chen K; Yuen JSP
Int J Urol; 2023 Nov; 30(11):991-999. PubMed ID: 37431969
[TBL] [Abstract][Full Text] [Related]
32. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
[TBL] [Abstract][Full Text] [Related]
33. Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Miura Y; Hatakeyama S; Narita S; Kimura T; Hata K; Yanagisawa T; Tanaka T; Ishi N; Kawamura S; Hoshi S; Ishidoya S; Mitsuzuka K; Ito A; Tsuchiya N; Egawa S; Habuchi T; Ohyama C
Prostate; 2022 Sep; 82(13):1304-1312. PubMed ID: 35747992
[TBL] [Abstract][Full Text] [Related]
34. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
35. Current management of metastatic castration-sensitive prostate cancer.
Kessel A; Kohli M; Swami U
Cancer Treat Res Commun; 2021; 28():100384. PubMed ID: 33951556
[TBL] [Abstract][Full Text] [Related]
36. First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.
Ferro M; Lucarelli G; Crocetto F; Dolce P; Verde A; La Civita E; Zappavigna S; de Cobelli O; Di Lorenzo G; Facchini BA; Scafuri L; Onofrio L; Porreca A; Busetto GM; Sonpavde G; Caraglia M; Klain M; Terracciano D; De Placido S; Buonerba C
Crit Rev Oncol Hematol; 2021 Jan; 157():103198. PubMed ID: 33316417
[TBL] [Abstract][Full Text] [Related]
37. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
38. Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
Lavoie JM; Zou K; Khalaf D; Eigl BJ; Kollmannsberger CK; Vergidis J; Noonan K; Zulfiqar M; Finch D; Chi KN
Prostate; 2019 Feb; 79(3):281-287. PubMed ID: 30370697
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.
Saad F; Chilelli A; Hui B; Muratov S; Ganguli A; North S; Shayegan B
J Med Econ; 2022; 25(1):583-590. PubMed ID: 35469527
[TBL] [Abstract][Full Text] [Related]
40. Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan.
Leith A; Kim J; Ribbands A; Clayton E; Yang L; Ghate SR
Adv Ther; 2022 May; 39(5):2236-2255. PubMed ID: 35316501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
